Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

110.68
+1.000.91%
Volume:1.67M
Turnover:184.25M
Market Cap:12.56B
PE:32.72
High:111.80
Open:109.72
Low:109.38
Close:109.68
52wk High:111.80
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:8.44
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:87.51
PE(LYR):43.23

Loading ...

May 10, 2021

Major Issues Report

8-K - Current report
May 10, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 05, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 03, 2021

Major Issues Report

8-K - Current report
Mar 01, 2021

Major Issues Report

8-K - Current report
Feb 25, 2021

Major Issues Report

8-K - Current report
Feb 23, 2021

Major Issues Report

8-K - Current report
Feb 23, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 23, 2021

Major Issues Report

8-K - Current report
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 26, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 13, 2021

Major Issues Report

8-K - Current report
Jan 11, 2021

Major Issues Report

8-K - Current report
Dec 08, 2020

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Nov 02, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]